var data={"title":"Toxic conjunctivitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Toxic conjunctivitis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/contributors\" class=\"contributor contributor_credentials\">Pedram Hamrah, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/contributors\" class=\"contributor contributor_credentials\">Reza Dana, MD, MPH, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/contributors\" class=\"contributor contributor_credentials\">Bruce S Bochner, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/contributors\" class=\"contributor contributor_credentials\">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/contributors\" class=\"contributor contributor_credentials\">Elizabeth TePas, MD, MS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 16, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are five main types of ocular allergy: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). Toxic conjunctivitis (also called toxic keratoconjunctivitis) is not allergic in nature, but it is frequently confused with allergic ocular disease. It implies direct damage to ocular tissues from an offending agent, usually a preservative or medication. The toxic agent can cause a papillary or follicular response in the conjunctiva with chronic use, and the conjunctiva can become chemotic, edematous, and hyperemic. Toxic conjunctivitis is reviewed here. The various forms of ocular allergy are reviewed separately. (See <a href=\"topic.htm?path=allergic-conjunctivitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Allergic conjunctivitis: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=vernal-keratoconjunctivitis\" class=\"medical medical_review\">&quot;Vernal keratoconjunctivitis&quot;</a> and <a href=\"topic.htm?path=atopic-keratoconjunctivitis\" class=\"medical medical_review\">&quot;Atopic keratoconjunctivitis&quot;</a> and <a href=\"topic.htm?path=giant-papillary-conjunctivitis\" class=\"medical medical_review\">&quot;Giant papillary conjunctivitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Toxic conjunctivitis typically occurs with protracted use of topical ocular medications [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/1\" class=\"abstract_t\">1</a>]. The reaction may take days to years to develop. There also appears to be a dose-response effect with regard to the preservative concentration and total amount of preservative-containing medications used [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/2\" class=\"abstract_t\">2</a>]. Thus, toxic ocular reactions are most frequently reported in patients with glaucoma, who are on lifelong therapy with multiple medications [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Results from a monkey model and human corneal epithelial cell culture suggest that preservatives in ophthalmic solutions are unlikely to cause significant direct toxicity to epithelium of otherwise normal cornea [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/4\" class=\"abstract_t\">4</a>]. However, studies in rabbit models consistently demonstrate ocular surface toxicity with topical preservative-containing medications [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3,5\" class=\"abstract_t\">3,5</a>]. In one study, patients with dry eyes were at greater risk for the development of toxic papillary reactions than those without dry eyes [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preservatives in eye medications, contact lens solutions, and <a href=\"topic.htm?path=artificial-tears-drug-information\" class=\"drug drug_general\">artificial tears</a> are the most common causes of toxic ocular reactions [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/7\" class=\"abstract_t\">7</a>]. The most common types of preservatives include benzalkonium chloride (BAK or BAC), thimerosal, chlorobutanol, sodium perborate, and stabilized oxychloro complex (SOC). All of these can cause toxic, irritant, or hypersensitivity reactions [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/8\" class=\"abstract_t\">8</a>]. However, in rabbit models, the newer-generation SOC is less cytotoxic than the other preservatives [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/1,3\" class=\"abstract_t\">1,3</a>].</p><p>A number of findings are seen in patients treated with preserved medications compared with those using preservative-free therapies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Goblet cell density is decreased in conjunctival epithelium [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/9\" class=\"abstract_t\">9</a>], and tear film break-up time is reduced [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subclinical inflammation of conjunctival epithelium is commonly seen [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3\" class=\"abstract_t\">3</a>]. Biopsies show an increase in surface expression of inflammatory markers and mediators, including human leukocyte antigen (HLA)-DR, intercellular adhesion molecule-1 (ICAM-1), and chemokine (C-C motif) receptors CCR4 and CCR5 [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3,9,10\" class=\"abstract_t\">3,9,10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Additional histopathologic findings include epithelial keratinization, squamous metaplasia, subconjunctival fibrosis, and increased apoptosis in the ocular epithelium [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3,10\" class=\"abstract_t\">3,10</a>].</p><p/><p>Toxic reactions to just about every eye medication have also been described [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/11-17\" class=\"abstract_t\">11-17</a>]. Among the more common toxic medicines are:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aminoglycoside antibiotics, such as <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> and <a href=\"topic.htm?path=tobramycin-drug-information\" class=\"drug drug_general\">tobramycin</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiviral agents, such as trifluorothymidine (Viroptic) and idoxuridine (Herplex)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glaucoma drops, such as <a href=\"topic.htm?path=brimonidine-drug-information\" class=\"drug drug_general\">brimonidine</a> (Alphagan), <a href=\"topic.htm?path=timolol-drug-information\" class=\"drug drug_general\">timolol</a> maleate (Timoptic), and <a href=\"topic.htm?path=pilocarpine-drug-information\" class=\"drug drug_general\">pilocarpine</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Topical anesthetics</p><p/><p>Cosmetics, such as mascara, creams, or hair spray, may also cause toxic ocular reactions [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">SIGNS AND SYMPTOMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conjunctival injection, chemosis, mucus discharge, papillary reaction of the palpebral conjunctiva, and itching are common. The eyelids can become swollen, thickened, and excoriated.</p><p>In mild cases of toxic conjunctivitis, the cornea will show punctate epithelial staining with <a href=\"topic.htm?path=fluorescein-drug-information\" class=\"drug drug_general\">fluorescein</a> dye application. In more severe cases, large epithelial erosions and corneal ulceration may develop. Degenerated epithelium can roll up and form pseudodendrites that are sometimes confused with herpetic dendrites.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinician should take a thorough history of all topical ocular medications used and their duration of usage. A common history is that the original eye condition improved upon initial treatment, but the eye symptoms worsened with continued use. The diagnosis is confirmed when the eyedrops are discontinued and the clinical manifestations resolve. Patch testing is rarely helpful for identification of the culprit since toxic conjunctivitis is a local reaction.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis includes the various forms of ocular allergy (seasonal and perennial allergic conjunctivitis [SAC and PAC], vernal and atopic keratoconjunctivitis [VKC and AKC], and giant papillary conjunctivitis [GPC]), allergic reactions to ophthalmic medications, and conjunctivitis medicamentosa. Toxic conjunctivitis can occur in addition to one of these conditions since most of these patients are treated with topical ophthalmic medications. (See <a href=\"topic.htm?path=allergic-conjunctivitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Allergic conjunctivitis: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=vernal-keratoconjunctivitis\" class=\"medical medical_review\">&quot;Vernal keratoconjunctivitis&quot;</a> and <a href=\"topic.htm?path=atopic-keratoconjunctivitis\" class=\"medical medical_review\">&quot;Atopic keratoconjunctivitis&quot;</a> and <a href=\"topic.htm?path=giant-papillary-conjunctivitis\" class=\"medical medical_review\">&quot;Giant papillary conjunctivitis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The eyelids can become swollen, thickened, and excoriated in toxic conjunctivitis. In contrast, these eyelid findings are unusual in the various forms of ocular allergy (the exception being AKC). In addition, ocular allergy more commonly presents with itching. Many times, the symptoms of toxic conjunctivitis are associated and coincide with use of eyedrops.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypersensitivity reactions to topical ocular medications typically occur early in the course of treatment, whereas toxic reactions usually occur after prolonged use.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conjunctivitis medicamentosa is caused by overuse of vasoconstricting eyedrops [<a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/20\" class=\"abstract_t\">20</a>]. It presents with increased conjunctival injection and rebound hyperemia that occurs when the medication is discontinued. It is thought to be similar to rhinitis medicamentosa that occurs with topical nasal decongestants.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recognition of the diagnosis of toxic conjunctivitis and removal of the offending agent(s) are imperative to the success of treating this condition. Stopping as many topical medications as feasible is a good first step. A preservative-free preparation should be used if a specific medication is required and preservative toxicity is suspected. An oral medication may be offered in situations in which a topical medication is causing toxicity, if that option is available. Cold compresses and preservative-free <a href=\"topic.htm?path=artificial-tears-drug-information\" class=\"drug drug_general\">artificial tears</a> or ointments may help with ocular irritation. The patient should be monitored closely by an ophthalmologist after the suspected agent is stopped if an infectious process is possible.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It implies direct damage to ocular tissues from an offending agent, usually a preservative or medication. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H3\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxic conjunctivitis most commonly occurs in patients on long-term therapy with multiple preservative-containing topical ocular medications, such as those with glaucoma. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conjunctival hyperemia is the most common manifestation. The eyelids and cornea may also be involved. (See <a href=\"#H4\" class=\"local\">'Signs and symptoms'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A common history is that the original eye condition improved upon initial treatment, but the eye symptoms worsened with continued use. (See <a href=\"#H5\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis includes the various forms of ocular allergy, hypersensitivity reactions to ophthalmic medications, and conjunctivitis medicamentosa. (See <a href=\"#H6\" class=\"local\">'Differential diagnosis'</a> above and <a href=\"topic.htm?path=allergic-conjunctivitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Allergic conjunctivitis: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=vernal-keratoconjunctivitis\" class=\"medical medical_review\">&quot;Vernal keratoconjunctivitis&quot;</a> and <a href=\"topic.htm?path=atopic-keratoconjunctivitis\" class=\"medical medical_review\">&quot;Atopic keratoconjunctivitis&quot;</a> and <a href=\"topic.htm?path=giant-papillary-conjunctivitis\" class=\"medical medical_review\">&quot;Giant papillary conjunctivitis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment involves discontinuing the suspected offending agent(s) and switching to preservative-free topical therapies or oral medications when possible if continued therapy is required. (See <a href=\"#H7\" class=\"local\">'Treatment'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/1\" class=\"nounderline abstract_t\">Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/2\" class=\"nounderline abstract_t\">Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/3\" class=\"nounderline abstract_t\">Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008; 86:716.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/4\" class=\"nounderline abstract_t\">Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol 2009; 9:5.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/5\" class=\"nounderline abstract_t\">Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008; 92:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/6\" class=\"nounderline abstract_t\">Wilson FM 2nd. Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc 1983; 81:854.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/7\" class=\"nounderline abstract_t\">Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008; 31:127.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/8\" class=\"nounderline abstract_t\">Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9:447.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/9\" class=\"nounderline abstract_t\">Pisella PJ, Lala E, Parier V, et al. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients]. J Fr Ophtalmol 2003; 26:675.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/10\" class=\"nounderline abstract_t\">Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5:459.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/11\" class=\"nounderline abstract_t\">FEDUKOWICZ H, WISE GN, ZARET MM. Toxic conjunctivitis due to antibiotics. Am J Ophthalmol 1955; 40:849.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/12\" class=\"nounderline abstract_t\">Benjamin KW. Toxicity of ocular medications. Int Ophthalmol Clin 1979; 19:199.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/13\" class=\"nounderline abstract_t\">Chen HT, Chen KH, Hsu WM. Toxic keratopathy associated with abuse of low-dose anesthetic: a case report. Cornea 2004; 23:527.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/14\" class=\"nounderline abstract_t\">Imperia PS, Lazarus HM, Dunkel EC, et al. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res 1988; 9:263.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/15\" class=\"nounderline abstract_t\">Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/16\" class=\"nounderline abstract_t\">Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000; 32:3.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/17\" class=\"nounderline abstract_t\">Coles WH. Pilocarpine toxicity. Effects on the rabbit corneal endothelium. Arch Ophthalmol 1975; 93:36.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/18\" class=\"nounderline abstract_t\">Ciolino JB, Mills DM, Meyer DR. Ocular manifestations of long-term mascara use. Ophthal Plast Reconstr Surg 2009; 25:339.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/19\" class=\"nounderline abstract_t\">S&aacute;nchez Palacios A, Shaman F, Garc&aacute; JA, S&aacute;nchez Palacios MA. [Prevalence of cosmetic sensitivity among beauticians]. Allergol Immunopathol (Madr) 1995; 23:148.</a></li><li><a href=\"https://www.uptodate.com/contents/toxic-conjunctivitis/abstract/20\" class=\"nounderline abstract_t\">Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94:134.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5555 Version 5.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">SIGNS AND SYMPTOMS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Differential diagnosis</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">TREATMENT</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=allergic-conjunctivitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Allergic conjunctivitis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atopic-keratoconjunctivitis\" class=\"medical medical_review\">Atopic keratoconjunctivitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=giant-papillary-conjunctivitis\" class=\"medical medical_review\">Giant papillary conjunctivitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vernal-keratoconjunctivitis\" class=\"medical medical_review\">Vernal keratoconjunctivitis</a></li></ul></div></div>","javascript":null}